Cargando…

CAR-T: What Is Next?

SIMPLE SUMMARY: In 2017, two chimeric antigen receptor-T (CAR-T) therapies were approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia. However, despite the breakthrough efficacy results, the safety of CAR-T treatment is still a concern for treating physicians and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Ju, Abila, Bams, Mostafa Kamel, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913679/
https://www.ncbi.nlm.nih.gov/pubmed/36765623
http://dx.doi.org/10.3390/cancers15030663

Ejemplares similares